Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In Milestones To Develop And Commercialize 4D-150 Across Asia-Pacific

Author: Benzinga Newsdesk | October 31, 2025 02:49am

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration
Up to $336 million in potential regulatory and commercial milestones and tiered double-digit royalties depending on net sales in Otsuka's territories
Proceeds and cost sharing expected to support global Phase 3 clinical trial in DME and pre-commercial activities

Posted In: FDMT